FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336707614> ?p ?o ?g. }

• W2336707614 endingPage "11936" @default.
• W2336707614 startingPage "11927" @default.
• W2336707614 abstract "Radioresistance of thoracic radiotherapy is a major bottleneck in the treatment of non-small cell lung cancer (NSCLC). Until now, there have been no effective biomarkers to predict the radiosensitivity. Based on miRNA profile screened from NSCLC cell lines with different radiosensitivity, this study was conducted to explore the correlation between plasma miRNAs and radiotherapy response in NSCLC patients, and to identify biomarkers of the radiosensitivity in NSCLC. Differentially expressed genes were acquired from time-series gene expression profiles of radioresistant H1299 and radiosensitive H460 lung cancer cells (GSE20549). Potential miRNAs were screened from these differentially expressed genes by combining bioinformatics with GO analysis, pathway analysis, and miRNA prediction. A clinical observational study was performed to explore the correlation between candidate miRNAs and radiotherapy response. Stage IIIa–IV NSCLC patients who received two to four cycles of previous chemotherapy and underwent thoracic radiotherapy alone were included. Total RNA was purified from peripheral blood before radiotherapy, and plasma miRNAs were detected by real-time PCR (qRT-PCR). Then, tumor response, progression-free survival (PFS), and overall survival (OS) were acquired. Four miRNAs significantly different between effective and ineffective groups were further analyzed to obtain cutpoints from receiver operating characteristic (ROC) curves and the predictive value of radiosensitivity. Candidate miRNAs included 14 miRNAs screened from radioresistant genes and five from radiosensitive genes. From Jan., 2013 to Dec., 2014, 54 eligible patients were enrolled with a median follow-up of 15.3 months (range 4.6 to 31.4) by the deadline of Aug. 31, 2015. Totally, there were no case of complete response (CR), 15 of partial response (PR), 35 of stable disease (SD), and 4 of progressive disease (PD). Eight patients had no progression and 19 patients were still alive. The median PFS and OS were 6.6 months (range 2.3 to 29.3) and 15.3 months (range 4.6 to 31.4), respectively. Four miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p, and hsa-miR-613) demonstrated a higher expression in effective group (CR + PR, 15 cases) than in ineffective group (SD + PD, 39 cases). Based on each cutpoint, objective response rate (ORR) was higher in miR-high group than in miR-low group. No miRNA showed correlation with median PFS or OS. Bioinformatical analysis and clinical verification reveal the correlation between plasma miRNAs and radiosensitivity in NSCLC patients. Plasma miRNAs represent novel biomarkers to predict radiotherapy response clinically." @default.
• W2336707614 created "2016-06-24" @default.
• W2336707614 creator A5021031204 @default.
• W2336707614 creator A5023930365 @default.
• W2336707614 creator A5033704842 @default.
• W2336707614 creator A5039204989 @default.
• W2336707614 creator A5050583771 @default.
• W2336707614 creator A5061294959 @default.
• W2336707614 creator A5073028085 @default.
• W2336707614 creator A5081021133 @default.
• W2336707614 creator A5086326013 @default.
• W2336707614 creator A5087030832 @default.
• W2336707614 creator A5090232873 @default.
• W2336707614 date "2016-04-13" @default.
• W2336707614 modified "2023-10-15" @default.
• W2336707614 title "Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer" @default.
• W2336707614 cites W1551455623 @default.
• W2336707614 cites W1655479748 @default.
• W2336707614 cites W1658218471 @default.
• W2336707614 cites W1856690487 @default.
• W2336707614 cites W1910034249 @default.
• W2336707614 cites W1940595181 @default.
• W2336707614 cites W1966566182 @default.
• W2336707614 cites W1974223688 @default.
• W2336707614 cites W1980215559 @default.
• W2336707614 cites W1991427152 @default.
• W2336707614 cites W1993112284 @default.
• W2336707614 cites W2002108741 @default.
• W2336707614 cites W2005274097 @default.
• W2336707614 cites W2018754160 @default.
• W2336707614 cites W2019394924 @default.
• W2336707614 cites W2040207029 @default.
• W2336707614 cites W2043853087 @default.
• W2336707614 cites W2044860252 @default.
• W2336707614 cites W2047146433 @default.
• W2336707614 cites W2051742304 @default.
• W2336707614 cites W2056560363 @default.
• W2336707614 cites W2063578239 @default.
• W2336707614 cites W2068020620 @default.
• W2336707614 cites W2068499515 @default.
• W2336707614 cites W2083135240 @default.
• W2336707614 cites W2097331409 @default.
• W2336707614 cites W2100980793 @default.
• W2336707614 cites W2105797313 @default.
• W2336707614 cites W2106787323 @default.
• W2336707614 cites W2112657305 @default.
• W2336707614 cites W2131988196 @default.
• W2336707614 cites W2133290549 @default.
• W2336707614 cites W2139992910 @default.
• W2336707614 cites W2146169914 @default.
• W2336707614 cites W2163622835 @default.
• W2336707614 cites W2206248221 @default.
• W2336707614 cites W2410609692 @default.
• W2336707614 doi "https://doi.org/10.1007/s13277-016-5052-8" @default.
• W2336707614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5080326" @default.
• W2336707614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27075472" @default.
• W2336707614 hasPublicationYear "2016" @default.
• W2336707614 type Work @default.
• W2336707614 sameAs 2336707614 @default.
• W2336707614 citedByCount "68" @default.
• W2336707614 countsByYear W23367076142017 @default.
• W2336707614 countsByYear W23367076142018 @default.
• W2336707614 countsByYear W23367076142019 @default.
• W2336707614 countsByYear W23367076142020 @default.
• W2336707614 countsByYear W23367076142021 @default.
• W2336707614 countsByYear W23367076142022 @default.
• W2336707614 countsByYear W23367076142023 @default.
• W2336707614 crossrefType "journal-article" @default.
• W2336707614 hasAuthorship W2336707614A5021031204 @default.
• W2336707614 hasAuthorship W2336707614A5023930365 @default.
• W2336707614 hasAuthorship W2336707614A5033704842 @default.
• W2336707614 hasAuthorship W2336707614A5039204989 @default.
• W2336707614 hasAuthorship W2336707614A5050583771 @default.
• W2336707614 hasAuthorship W2336707614A5061294959 @default.
• W2336707614 hasAuthorship W2336707614A5073028085 @default.
• W2336707614 hasAuthorship W2336707614A5081021133 @default.
• W2336707614 hasAuthorship W2336707614A5086326013 @default.
• W2336707614 hasAuthorship W2336707614A5087030832 @default.
• W2336707614 hasAuthorship W2336707614A5090232873 @default.
• W2336707614 hasBestOaLocation W23367076141 @default.
• W2336707614 hasConcept C104317684 @default.
• W2336707614 hasConcept C121608353 @default.
• W2336707614 hasConcept C126322002 @default.
• W2336707614 hasConcept C143998085 @default.
• W2336707614 hasConcept C145059251 @default.
• W2336707614 hasConcept C206684579 @default.
• W2336707614 hasConcept C2776256026 @default.
• W2336707614 hasConcept C502942594 @default.
• W2336707614 hasConcept C509974204 @default.
• W2336707614 hasConcept C54355233 @default.
• W2336707614 hasConcept C58962609 @default.
• W2336707614 hasConcept C60644358 @default.
• W2336707614 hasConcept C71924100 @default.
• W2336707614 hasConcept C86803240 @default.
• W2336707614 hasConceptScore W2336707614C104317684 @default.
• W2336707614 hasConceptScore W2336707614C121608353 @default.
• W2336707614 hasConceptScore W2336707614C126322002 @default.
• W2336707614 hasConceptScore W2336707614C143998085 @default.

• next